225 related articles for article (PubMed ID: 33964453)
21. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
[TBL] [Abstract][Full Text] [Related]
22. Buckling surgery and supplemental intravitreal bevacizumab or photocoagulation on stage 4 retinopathy of prematurity eyes.
Futamura Y; Asami T; Nonobe N; Kachi S; Ito Y; Sato Y; Hayakawa M; Terasaki H
Jpn J Ophthalmol; 2015 Nov; 59(6):378-88. PubMed ID: 26265249
[TBL] [Abstract][Full Text] [Related]
23. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
Toy BC; Schachar IH; Tan GS; Moshfeghi DM
Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
[TBL] [Abstract][Full Text] [Related]
24. OUTCOMES OF NONCONFLUENT DIODE LASER PANRETINAL PHOTOCOAGULATION FOR AGGRESSIVE POSTERIOR RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB.
Mammo DA; Rubino SM; Quiram PA
Retina; 2021 Apr; 41(4):706-710. PubMed ID: 32796444
[TBL] [Abstract][Full Text] [Related]
25. Anterior segment ischemia after laser for retinopathy of prematurity previously treated with antivascular endothelial growth factor.
Castillejo Becerra CM; Mansukhani SA; Sagaser SD; Mammo DA; Bothun ED; Quiram PA; Mohney BG
J AAPOS; 2021 Jun; 25(3):155.e1-155.e5. PubMed ID: 34044115
[TBL] [Abstract][Full Text] [Related]
26. A comparison of primary laser versus laser after anti-vascular endothelial growth factor for type 1 retinopathy of prematurity.
Lajoie JE; Pacheco RR; Shah V; Tauber KA; Binenbaum G; Barry GP
J AAPOS; 2022 Aug; 26(4):191.e1-191.e4. PubMed ID: 35863608
[TBL] [Abstract][Full Text] [Related]
27. The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review.
Chow SC; Lam PY; Lam WC; Fung NSK
Eye (Lond); 2022 Aug; 36(8):1532-1545. PubMed ID: 35017699
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal bevacizumab for exudative retinal detachment post laser therapy for retinopathy of prematurity.
Ehmann D; Greve M
Can J Ophthalmol; 2014 Apr; 49(2):228-31. PubMed ID: 24767234
[TBL] [Abstract][Full Text] [Related]
29. Treatment of retinopathy of prematurity (ROP) outside International Classification of ROP (ICROP) guidelines.
Rajan RP; Kohli P; Babu N; Dakshayini C; Tandon M; Ramasamy K
Graefes Arch Clin Exp Ophthalmol; 2020 Jun; 258(6):1205-1210. PubMed ID: 32322963
[TBL] [Abstract][Full Text] [Related]
30. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
Chandra P; Kumawat D; Agarwal D; Chawla R
J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
[TBL] [Abstract][Full Text] [Related]
31. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
Han J; Kim SE; Lee SC; Lee CS
Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
[TBL] [Abstract][Full Text] [Related]
32. A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity.
Khodabande A; Niyousha MR; Roohipoor R
J AAPOS; 2016 Dec; 20(6):490-492. PubMed ID: 27794470
[TBL] [Abstract][Full Text] [Related]
33. Reactivation of retinopathy of prematurity after ranibizumab treatment.
Wong RK; Hubschman S; Tsui I
Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
[TBL] [Abstract][Full Text] [Related]
34. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.
Chung EJ; Kim JH; Ahn HS; Koh HJ
Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1727-30. PubMed ID: 17690897
[TBL] [Abstract][Full Text] [Related]
35. Characteristics of Severe Retinopathy of Prematurity in Infants with Birth Weight above 1500 Grams at a Referral Center in Turkey.
Gunay M; Celik G; Tuten A; Karatekin G; Bardak H; Ovali F
PLoS One; 2016; 11(8):e0161692. PubMed ID: 27548628
[TBL] [Abstract][Full Text] [Related]
36. A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity.
Chang E; Josan AS; Purohit R; Patel CK; Xue K
Ophthalmology; 2022 Dec; 129(12):1389-1401. PubMed ID: 35842190
[TBL] [Abstract][Full Text] [Related]
37. A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity.
Chen TA; Shields RA; Bodnar ZH; Callaway NF; Schachar IH; Moshfeghi DM
Am J Ophthalmol; 2019 Feb; 198():63-69. PubMed ID: 30312578
[TBL] [Abstract][Full Text] [Related]
38. Slow progressive perifoveal vascular formation in an infant with aggressive posterior retinopathy of prematurity.
Chen X; Imperio R; Seely KR; Viehland C; Izatt JA; Prakalapakorn SG; Freedman SF; Toth CA
J AAPOS; 2020 Oct; 24(5):323-326. PubMed ID: 33045380
[TBL] [Abstract][Full Text] [Related]
39. A rare case of aggressive posterior retinopathy of prematurity presenting with exudative retinal detachment.
Mittal K; Chawla R; Vukkadala T; Azad SV; Vohra R; Daga J
J AAPOS; 2021 Feb; 25(1):47-50. PubMed ID: 33144201
[TBL] [Abstract][Full Text] [Related]
40. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity.
Erol MK; Coban DT; Sari ES; Bilgin AB; Dogan B; Ozdemir O; Tunay ZO
Arq Bras Oftalmol; 2015; 78(6):340-3. PubMed ID: 26677033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
